Physician
South Florida Baptist Hospital INC
South Florida Baptist Hospital INC was paid $12.83M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoSOUTH FLORIDA BAPTIST HOSPITAL INC
PLANT CITY, FL 33563
PLANT CITY, FL 33563
33aNPI1548205883assigned 06/19/2006
33bProvider typeObstetrics & Gynecology Physician
28Total paid$12.83M
24GClaims426,668
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in Florida
Rank by total paid#5 of 352
Median peer was paid$67K
This provider vs. median193×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GORKEN, LYNDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,395 | $490K | |
| 2019 | 97,641 | $2.71M | |
| 2020 | 80,746 | $2.02M | |
| 2021 | 85,578 | $2.34M | |
| 2022 | 74,662 | $2.80M | |
| 2023 | 37,178 | $1.70M | |
| 2024incomplete | 16,468 | $782K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 22,751 | 20,722 | $2.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 23,077 | 18,548 | $1.73M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 20,622 | 4,396 | $1.63M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.3% | 11,638 | 2,623 | $938K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 10,996 | 8,499 | $730K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.0% | 11,294 | 2,547 | $644K |
| 80053 | Comprehensive metabolic panel | 4.3% | 19,519 | 15,439 | $553K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 3,096 | 2,751 | $479K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 3,394 | 3,167 | $303K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 3,370 | 2,656 | $251K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 3,846 | 3,203 | $239K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.7% | 4,280 | 3,650 | $213K |
170 more codes
| 59899 | 1.4% | 1,242 | $182K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 8,967 | $173K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,711 | $149K |
| 81003 | 1.0% | 16,373 | $130K | |
| 97803 | <1% | 1,047 | $121K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,183 | $109K |
| 87631 | <1% | 1,568 | $96K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 149 | $94K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 239 | $89K |
| 59025 | Fetal non-stress test | <1% | 811 | $85K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,606 | $83K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,899 | $83K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,589 | $82K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,632 | $71K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,371 | $70K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 727 | $69K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,172 | $63K |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,732 | $61K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,896 | $58K |
| G0378 | Hospital observation service, per hour | <1% | 7,476 | $55K |
| 97161 | <1% | 721 | $53K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,821 | $53K |
| 97162 | <1% | 402 | $50K | |
| 97802 | <1% | 340 | $44K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 976 | $38K |
| 81025 | <1% | 2,026 | $37K | |
| 92526 | <1% | 543 | $33K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,807 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,220 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,646 | $30K |
| 87641 | <1% | 541 | $30K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 661 | $30K |
| 92523 | <1% | 268 | $30K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,943 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,875 | $24K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 715 | $23K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,114 | $22K |
| 82948 | <1% | 6,856 | $22K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 950 | $21K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,548 | $18K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,145 | $17K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 372 | $17K |
| 73630 | <1% | 372 | $14K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 172 | $14K |
| 97167 | <1% | 111 | $13K | |
| 97163 | <1% | 125 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 651 | $12K |
| 73130 | <1% | 290 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 662 | $12K |
| 84702 | <1% | 1,988 | $12K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 227 | $11K |
| 0100U | <1% | 214 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,239 | $11K |
| 73564 | <1% | 246 | $11K | |
| 73610 | <1% | 278 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,036 | $10K |
| 84484 | <1% | 7,921 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,811 | $9K |
| 97750 | <1% | 198 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,199 | $8K |
| A9270 | Non-covered item or service | <1% | 2,233 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,552 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,036 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 189 | $7K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 35 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,885 | $6K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,458 | $6K |
| 76801 | <1% | 1,317 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,482 | $6K |
| 83880 | <1% | 2,357 | $6K | |
| 86900 | <1% | 1,594 | $5K | |
| 93971 | <1% | 304 | $5K | |
| 96367 | <1% | 201 | $5K | |
| 80061 | Lipid panel | <1% | 1,214 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,211 | $5K |
| 84703 | <1% | 5,878 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,830 | $3K |
| 83735 | <1% | 2,953 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,510 | $3K |
| 97014 | <1% | 63 | $3K | |
| 85610 | <1% | 2,809 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 655 | $3K |
| 87077 | <1% | 1,459 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 138 | $3K |
| 87186 | <1% | 1,230 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 148 | $2K |
| 73030 | <1% | 213 | $2K | |
| 85730 | <1% | 1,651 | $2K | |
| J3490 | Unclassified drugs | <1% | 848 | $2K |
| 87040 | <1% | 1,483 | $2K | |
| 83690 | <1% | 4,557 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,536 | $2K |
| 93970 | <1% | 75 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 985 | $2K |
| J1815 | Injection, insulin, per 5 units | <1% | 989 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 209 | $2K |
| 85027 | <1% | 1,762 | $2K | |
| 85380 | <1% | 655 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 29 | $1K |
| 73110 | <1% | 15 | $1K | |
| 87660 | <1% | 1,592 | $1K | |
| 87510 | <1% | 1,589 | $1K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 49 | $1K |
| 97116 | <1% | 27 | $1K | |
| 83605 | <1% | 1,194 | $1K | |
| 87480 | <1% | 1,590 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 775 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 779 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 45 | $1K |
| 74018 | <1% | 90 | $987.79 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 34 | $883.32 |
| 72100 | <1% | 56 | $852.72 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 416 | $766.83 |
| 71250 | <1% | 30 | $720.14 | |
| 72040 | <1% | 13 | $715.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,001 | $708.23 |
| 84145 | <1% | 364 | $708.01 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 192 | $683.22 |
| 86901 | <1% | 1,570 | $602.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 638 | $568.82 |
| 87581 | <1% | 638 | $558.61 | |
| 87486 | <1% | 637 | $558.61 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 344 | $480.72 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,929 | $466.52 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,448 | $415.95 |
| 73090 | <1% | 12 | $388.28 | |
| 96376 | <1% | 196 | $385.83 | |
| 70486 | <1% | 14 | $371.22 | |
| 12011 | <1% | 15 | $327.86 | |
| 76642 | <1% | 14 | $286.95 | |
| 86850 | <1% | 193 | $227.91 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 127 | $212.55 |
| 84100 | <1% | 247 | $207.19 | |
| 73560 | <1% | 17 | $173.28 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,038 | $168.69 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 468 | $159.09 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 335 | $137.32 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 32 | $129.16 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 207 | $90.54 |
| 87640 | <1% | 366 | $69.59 | |
| 0240U | <1% | 99 | $69.59 | |
| 73502 | <1% | 16 | $69.05 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 14 | $56.11 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 108 | $46.63 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,440 | $46.15 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 17 | $40.39 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 150 | $29.12 |
| 90715 | <1% | 31 | $23.90 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31 | $23.90 |
| 82150 | <1% | 46 | $12.21 | |
| 87430 | <1% | 27 | $8.88 | |
| 90686 | <1% | 21 | $7.28 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 25 | $2.70 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 112 | $1.11 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 55 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 106 | $0.00 |
| 0353U | 0% | 32 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 15 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 22 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 331 | $0.00 |
| 87205 | 0% | 31 | $0.00 | |
| 82550 | 0% | 68 | $0.00 | |
| 87070 | 0% | 14 | $0.00 | |
| 86140 | 0% | 62 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 121 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 22 | $0.00 |
| 82077 | 0% | 31 | $0.00 | |
| 81001 | 0% | 14 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 19 | $0.00 |
| 87340 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGORKEN, LYNDA (VICE PRESIDENT, PFS DIVISION)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.